PM
REGN icon

Penbrook Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Penbrook Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$607K Sell
785
-12
-2% -$9.19K 0.46% 54
2025
Q4 		$615K Hold
797
– – 0.42% 54
2025
Q3 		$448K Sell
797
-897
-53% -$507K 0.31% 62
2025
Q2 		$987K Buy
1,694
+797
+89% +$445K 0.37% 58
2025
Q1 		$569K Hold
897
– – 0.43% 52
2024
Q4 		$639K Sell
897
-250
-22% -$210K 0.44% 49
2024
Q3 		$1.21M Hold
1,147
– – 0.78% 28
2024
Q2 		$1.21M Hold
1,147
– – 0.74% 28
2024
Q1 		$1.1M Hold
1,147
– – 0.68% 32
2023
Q4 		$1.01M Buy
1,147
+100
+10% +$82.3K 0.68% 33
2023
Q3 		$862K Buy
1,047
+25
+2% +$19.6K 0.63% 38
2023
Q2 		$734K Sell
1,022
-50
-5% -$38.5K 0.53% 44
2023
Q1 		$881K Hold
1,072
– – 0.67% 41
2022
Q4 		$773K Sell
1,072
-200
-16% -$148K 0.66% 43
2022
Q3 		$876K Hold
1,272
– – 0.75% 36
2022
Q2 		$752K Hold
1,272
– – 0.59% 51
2022
Q1 		$888K Hold
1,272
– – 0.58% 54
2021
Q4 		$803K Hold
1,272
– – 0.48% 62
2021
Q3 		$770K Hold
1,272
– – 0.48% 64
2021
Q2 		$710K Buy
1,272
+462
+57% +$234K 0.43% 65
2021
Q1 		$383K Buy
+810
New +$394K 0.28% 82

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Penbrook Management's REGN Position: Q1 2026 in Review

Penbrook Management reduced its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q1 2026, selling an estimated $9.19K and leaving 785 shares worth $607K. The position accounts for 0.46% of the portfolio, ranked #54.

Penbrook Management first reported a position in REGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.21M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Penbrook Management held 785 shares of Regeneron Pharmaceuticals worth $607K as of Q1 2026.
  • Penbrook Management sold 12 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $9.19K.
  • Regeneron Pharmaceuticals made up 0.46% of Penbrook Management's portfolio in Q1 2026, its #54 holding.
  • Penbrook Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Penbrook Management's Regeneron Pharmaceuticals position peaked at $1.21M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Penbrook Management's 13F filing for Q1 2026, filed 21 Apr 2026.